ZNF337 Antibody

What is ZNF337 and why is it significant for cancer research?

ZNF337 (Zinc Finger Protein 337) is a novel member of the Zinc Finger (ZNF) protein family, located on human chromosome 20 (20p11.21). The protein contains 751 amino acids and is encoded by a gene with 6 exons . ZNF337 has gained significant attention in cancer research due to its abnormal expression across multiple cancer types, particularly in kidney renal clear cell carcinoma (KIRC) .

Research demonstrates that ZNF337 may function in transcriptional regulation through its zinc finger domains, which enable DNA binding and other molecular functions . Recent pan-cancer analysis revealed that ZNF337 has potential value as both a diagnostic and prognostic biomarker, with particularly strong associations with KIRC progression and patient survival outcomes .

Proper storage and handling of ZNF337 antibodies is critical for maintaining their activity:

• Storage temperature: Store at -20°C for long-term storage. Some antibodies may be stored at 4°C for short periods .

• Aliquoting: Upon receipt, aliquot the antibody to avoid repeated freeze-thaw cycles which can degrade activity .

• Buffer conditions: Most ZNF337 antibodies are supplied in PBS with sodium azide (0.02-0.09%) and glycerol (50%) to maintain stability .

• Shipping conditions: Antibodies are typically shipped with polar packs and should be stored immediately at recommended temperatures upon receipt .

• Expiration: Commercial antibodies are typically guaranteed for 1 year from date of receipt when stored properly .

Following these guidelines helps ensure consistent experimental results and prevents premature degradation of the antibody.

How can I validate the specificity of a ZNF337 antibody for my particular research application?

To validate ZNF337 antibody specificity for your research:

• Positive and negative controls: Include known ZNF337-expressing cells (e.g., Jurkat cells) as positive controls and cells with low/no ZNF337 expression as negative controls .

• Knockdown/knockout validation: Use siRNA knockdown or CRISPR knockout of ZNF337 to confirm antibody specificity. Research has demonstrated knockdown approaches in Caki-1 and 786-O cell lines that can serve as models .

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to your samples. Signal reduction indicates specific binding.

• Multiple antibody verification: Use antibodies from different vendors or those recognizing different epitopes of ZNF337 to confirm your findings.

• Molecular weight verification: Confirm that the detected band matches the predicted molecular weight of ZNF337 (approximately 86.9 kDa, though post-translational modifications may affect migration) .

The method employed in the pan-cancer analysis study used multiple validation approaches, including Western blotting confirmation with qRT-PCR validation of knockdown efficiency, providing a robust model for comprehensive validation .

What experimental protocols have been successful for studying ZNF337's role in cancer progression?

Based on published research, the following protocols have been effective for studying ZNF337 in cancer:

• Gene expression analysis in patient samples:

  • The pan-cancer analysis utilized TCGA and GTEx databases to analyze ZNF337 expression across multiple cancer types .

  • qRT-PCR of patient tissue samples showed significantly higher ZNF337 expression in KIRC tissues compared to adjacent normal tissues .

• Cell proliferation assays:

  • CCK-8 experiment: After ZNF337 knockdown, cell viability was significantly decreased in Caki-1 and 786-O cell lines over 24-72 hours .

  • Colony formation experiment: Knockdown of ZNF337 reduced the number of colonies in KIRC cell lines .

  • EdU experiment: Used to verify that ZNF337 knockdown reduced proliferative capacity of cancer cells .

• Cell migration assays:

  • Transwell assay: Demonstrated that ZNF337 knockdown suppressed migration of KIRC cells .

  • Wound healing experiment: Showed reduced migration ability in ZNF337 knockdown cells .

• Correlation with immune infiltration:

  • Multiple algorithms (TIDE, XCELL, MCPCOUNTER, EPIC) were used to investigate correlations between ZNF337 expression and cancer-associated fibroblasts (CAFs) in pan-cancer analysis .

  • TIMER algorithm helped analyze immune cell infiltration, including B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells .

How can ZNF337 antibodies be used to investigate relationships between ZNF337 and immune checkpoint genes?

Recent research has revealed significant correlations between ZNF337 expression and immune checkpoint genes, suggesting potential implications for immunotherapy. To investigate these relationships:

• Co-expression analysis:

  • Use ZNF337 antibodies with immunoblotting or immunohistochemistry alongside detection of immune checkpoint proteins (e.g., CTLA-4, PD-1) to analyze co-expression patterns.

  • In KIRC, ZNF337 expression positively correlated with 53 out of 60 immune checkpoint genes, including CTLA-4 and PDCD1 .

• Multiplex immunofluorescence:

  • Combined detection of ZNF337 with immune checkpoint proteins in tissue sections can reveal spatial relationships and co-expression at the cellular level.

• Flow cytometry:

  • Use ZNF337 antibodies in combination with immune checkpoint antibodies to quantify co-expression in cell suspensions from tumors.

• Functional assays:

  • After modulating ZNF337 expression (knockdown/overexpression), measure changes in immune checkpoint gene expression using qRT-PCR or Western blotting.

  • Assess functional consequences using T cell activation assays or tumor-immune co-culture systems.

The methodology should be tailored to your specific research question, with consideration of cancer type, as the relationship between ZNF337 and immune checkpoint genes varies significantly between cancer types (positive in KIRC, DLBC, LIHC, OV, and UVM; negative in BLCA, GBM, LGG, and SARC) .

What are common challenges when using ZNF337 antibodies and how can they be addressed?

How should I optimize Western blot conditions for detecting ZNF337?

For optimal ZNF337 detection by Western blot:

• Sample preparation:

  • Use RIPA buffer with protease inhibitors for efficient extraction

  • Load 10-30 μg of total protein per lane

• Gel selection and transfer:

  • Use 8-10% SDS-PAGE gels to resolve the expected 86.9 kDa protein

  • Transfer to PVDF membrane at 100V for 60-90 minutes or overnight at 30V

• Blocking and antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

  • Incubate with primary antibody (1:500-1:2000) overnight at 4°C

  • Wash 3-5 times with TBST

  • Incubate with appropriate HRP-conjugated secondary antibody (1:5000-1:10000) for 1 hour at room temperature

• Detection:

  • Use enhanced chemiluminescence (ECL) detection system

  • Expose to film or use digital imaging

  • Expected molecular weight is approximately 86.9 kDa, though post-translational modifications may result in 70 kDa bands as well

• Controls:

  • Include loading control (β-actin, GAPDH)

  • Include positive control lysate (e.g., Jurkat cells)

How has ZNF337 been implicated in cancer prognosis, and what methods were used to establish these connections?

Recent comprehensive pan-cancer analysis has revealed significant correlations between ZNF337 expression and cancer prognosis:

These findings suggest that ZNF337 antibodies could be valuable tools for prognostic studies, particularly in kidney cancer research.

What is the relationship between ZNF337 and the tumor microenvironment?

Research has revealed important connections between ZNF337 and tumor microenvironment components:

• Cancer-associated fibroblasts (CAFs):

  • ZNF337 expression positively correlated with the estimated infiltration value of CAFs in most tumors, as determined through TIDE, XCELL, MCPCOUNTER, and EPIC algorithms .

  • This suggests ZNF337 may influence tumor progression by modulating CAF activity in the tumor microenvironment.

• Immune cell infiltration:

  • TIMER analysis showed significant correlations between ZNF337 expression and tumor purity and immune cell infiltration .

  • Specific correlations were observed with:

    • B cells

    • CD8+ T cells

    • CD4+ T cells

    • Macrophages

    • Neutrophils

    • Dendritic cells

  • These correlations were particularly notable in KIRC, KIRP, BLCA, BRCA, HNSC, STAD, and THCA .

• Immune checkpoint genes:

  • In KIRC, ZNF337 expression showed positive correlations with 53 out of 60 immune checkpoint genes .

  • Similar positive correlations were observed in DLBC, LIHC, OV, and UVM .

  • Negative correlations were observed in BLCA, GBM, LGG, and SARC .

These findings suggest that ZNF337 antibodies could be valuable tools for studying tumor microenvironment interactions, potentially informing immunotherapy approaches.

What are promising methodological approaches for further investigating ZNF337's role in cancer and immunotherapy?

Based on current findings, several methodological approaches show promise for advancing ZNF337 research:

• Single-cell transcriptomics and proteomics:

  • Application of ZNF337 antibodies in single-cell proteomics could reveal cell type-specific expression patterns within the tumor microenvironment.

  • Integration with transcriptomic data would provide comprehensive understanding of ZNF337's regulatory networks.

• Chromatin immunoprecipitation (ChIP-seq):

  • As ZNF337 is likely involved in transcriptional regulation , ChIP-seq using ZNF337 antibodies could identify its DNA binding sites and target genes.

  • Integration with RNA-seq data from ZNF337 knockdown/overexpression experiments would validate transcriptional targets.

• Proximity-dependent biotinylation (BioID or TurboID):

  • Identifying ZNF337 protein interaction partners could reveal its molecular mechanisms in cancer progression.

  • This approach could be particularly valuable for understanding how ZNF337 influences immune checkpoint gene expression.

• Immunotherapy response prediction:

  • Development of diagnostic assays using ZNF337 antibodies to predict patient response to immune checkpoint inhibitors, particularly in cancers where ZNF337 correlates with immune checkpoint genes.

  • Combination of ZNF337 expression with other biomarkers could improve prediction accuracy.

• CRISPR-based functional genomics:

  • Systematic investigation of ZNF337's role in cancer cell phenotypes and immune interactions using CRISPR knockout/activation screens.

  • Validation of findings using ZNF337 antibodies in complementary approaches.

These methodological approaches, combined with the continued use and refinement of ZNF337 antibodies, hold promise for deepening our understanding of this protein's role in cancer biology and therapeutic response.

Technical Specifications of Commercial ZNF337 Antibodies

This technical information should assist researchers in selecting and using the appropriate ZNF337 antibody for their specific research applications.